ArticleMicroorganisms2022
Multidrug-Resistant
Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2024Pooled it
- Risk factors associated with carbapenem-resistant Gram-negative bacterial infections in intensive care units in Jordan.BMC infectious diseases · 2026Article
- Comparative Population Genomics and Machine Learning Reveal a Distinct Regional Genomic Fingerprint of Middle EasternMicroorganisms · 2026Article
- Multidrug-resistant Acinetobacter spp. bloodstream infections in hematologic patients: clinical characteristics, genomic features, and eravacycline-based combination therapy.BMC infectious diseases · 2026Article
- Prevalence and Resistance Profiles ofAntibiotics (Basel, Switzerland) · 2025Review
- Incidence of drug resistance and expression ofIranian journal of microbiology · 2025Article
- Beyond Culture: Real-Time PCR Performance in Detecting Causative Pathogens and Key Antibiotic Resistance Genes in Hospital-Acquired Pneumonia.Antibiotics (Basel, Switzerland) · 2025Article
- Phenotypical and Molecular Characterization ofLife (Basel, Switzerland) · 2025Article
- Detection of AdeAB, TetA, and TetB efflux pump genes in clinical isolates of tetracycline-resistant Acinetobacter baumannii from patients of Suez Canal University Hospitals.BMC microbiology · 2025Article
- Molecular Epidemiology and MLST-Based Typing of Pandrug-ResistantIranian journal of pathology · 2025Article
- Monitoring of Antibiotic Resistance Patterns Within Al-Karak Governmental Hospital, Jordan, in 2022.Antibiotics (Basel, Switzerland) · 2024Article
- The context of blaBMC research notes · 2024Article
- Retrospective Analysis of Antimicrobial Resistance Trends in Pseudomonas aeruginosa and Acinetobacter baumannii.Cureus · 2024Article
- Epidemiological and Clinical Insights intoInternational journal of general medicine · 2024Article
- Nosocomial, Healthcare-Associated, and Community-AcquiredInfection and drug resistance · 2024Article
- Carbapenem-resistantIJID regions · 2023Article
- Acinetobacter baumannii: assessing susceptibility patterns, management practices, and mortality predictors in a tertiary teaching hospital in Lebanon.Antimicrobial resistance and infection control · 2023Observational
- Alterations in gene expression ofJournal of medicine and life · 2023Article
- Occurrence of Multidrug-Resistant Strains ofTropical medicine and infectious disease · 2023Article
- Epidemiology and antimicrobial resistance trends ofFrontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Background: Acinetobacter baumannii is a common cause of multi-drug (MDR)-resistant infections worldwide. The epidemiological and molecular characteristics of MDR-A. baumannii in Jordan is not known. Methods: A. baumannii isolates were collected from 2010 to 2020 from three tertiary hospitals in Jordan. Demographic and clinical data, isolates information, antibiotic susceptibility patterns, phenotypic, and molecular characterization of carbapenem resistance genes were performed. Results: A total of 622 A. baumannii isolates were collected during the study period. Most isolates were from males, aged 18−60 years, Jordanian, from infected wounds, and were patients in surgery or critical care units. Among patients from whom A. baumannii was isolated, associated risk factors for MDR were adults over 60, males, critically ill patients and infected wounds (OR 4.14, 2.45, 10, 7, respectively, p < 0.0001). Incidence rates from 2010 to 2015 showed a slight increase in MDR (3.75/1000 to 4.46/1000). Resistance patterns indicated high resistance for most cephalosporins, carbapenems, and fluoroquinolones, moderate resistance for trimethoprim/sulfamethoxazole and ampicillin/sulbactam, low resistance for aminoglycosides and tetracyclines, while colistin and tigecycline, have the lowest resistance rates. 76.8% of A. baumannii isolates were MDR and 99.2% were carbapenem-resistant. All isolates were positive for the OXA-51 gene (100%), 98.5% were positive for the OXA-23 gene, 26.6% for the VIM gene, while KPC and IMP genes were almost not detected (0% and 0.8% respectively). Conclusions: This is the first large, multicentric, prolonged study that provides insights into A. baumannii infections in Jordan. Attention to patients at higher risk is important for early identification. Colistin and tigecycline were the most effective antimicrobials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.